OR WAIT null SECS
Patricia Van Arnum was executive editor of Pharmaceutical Technology.
Boehringer Ingelheim and and Hisoar (Taizhou, China), a pharmaceutical production company, formed a strategic production alliance in China.
Ingelheim, Germany (Aug. 28)-Boehringer Ingelheim and Hisoar (Taizhou, China), a pharmaceutical production company, formed a strategic production alliance in China.
Boehringer Ingelheim says the agreement complements its production network for chemical intermediates for its active pharmaceutical ingredients (APIs). The intermediates will be processed further in Boehringer Ingelheim’s plants in Germany, Italy, Spain, and the US.
Under the agreement, Boehringer Ingelheim will supply production expertise and technical support to Hisoar. In turn, Hisoar will invest in new production facilities specifically for Boehringer Ingelheim at Hisoar’s new site in Chuannan, Zhejiang Province, China. Production for Boehringer Ingelheim in Chuannan is scheduled to start in early 2009.
“Boehringer Ingelheim is looking forward to a fruitful cooperation with our Chinese partner to have in [the] future more flexibility, short production timelines, and an appropriate capacity for the continuously growing demand for Boehringer Ingelheim’s medications across the globe,” said Hans-Jürgen Leuchs, member of the board of managing directors, in a company press release. Leuchs is responsible for the corporate board division operations of Boehringer Ingelheim.
Hisoar was founded in 1966 and focuses on production of intermediates for APIs. It has three production bases in China: Waisha, Guangdong; Chuannan, Zhejiang; and Quanfeng, Guangxi.